Loading...

HUMA HUMACYTE INC Other Situations 8-K Filing

HMCY

HM

HUMACYTE INC

(HUMA)

2023 8-K

Show Summary

Summary

Stock Splits, Stock Buyback...

Financial Statements

Financial Results

Investor Statement

Investor Presentation

Securities Offering

Q3 Financial Results

Clinical Trial Results

Stock Purchase Agreement

FDA Review Delay

Other Special Situation

Annual Meeting of Stockholders

Earnings Report

Earnings Reports

Underwriting Agreement

Investor Presentation

Other Special Situation

Earnings Report

Earnings Reports

Earnings Report

Earnings Report

External Links:

Humacyte, Inc. announced the completion of enrollment in its Phase 2/3 Vascular trauma trial (V005) to support the Biologics License Application filing for its human acellular vessel in extremity vascular trauma.

AI Assistant

HUMACYTE INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.